| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer |
|
Medicine details |
|
| Medicine name | fulvestrant (Faslodex®) |
| Formulation | solution for injection |
| Reference number | 1475 |
| Indication | Treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/07/2017 |
| NICE guidance | TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer |